image

Adoptive Cell Therapy

Innovative Drugs Designed to Improve Patients’ Lives

Our pipeline includes internally discovered and wholly owned drug-candidates designed to treat patients with hematologic malignancies, solid tumors, autoimmune diseases, and viral diseases. It comprises both Chimeric Targeting Molecules (CTMs) for targeted protein degradation to eliminate disease causing proteins and Ligase Inhibitors that target key control elements in immune regulation. Drug discovery alliances with Gilead Sciences and Sanofi further enhance our pipeline, each focusing on the discovery and development of CTMs against a set of unique targets.

Drug-enhanced Cell Therapy Programs

Adoptive Cell Therapy

Nurix is pioneering applying targeted protein modulation to adoptive cell therapy.  Our lead cell therapy program applies a CBL-B inhibitor, NX-0255, to a cancer patient’s T cells outside the body (ex vivo) to enhance their tumor-killing ability when returned to the patient as an autologous cell therapy. Inhibiting CBL-B has several beneficial effects that enhance adoptive T cell therapy, including stimulation of IL-2 secretion, increased T cell proliferation, reduced T cell exhaustion, and a skewing of the phenotype of the T-cells for improved clinical outcomes.

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryLead OptimizationPreclinicalPhase 1Phase 2Phase 3
Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio
NX-2127 BTK + IMiD Activity (Oral) B-cell malignancies

 

NX-5948 BTK (Oral) B-cell malignancies and autoimmune disease

 

KINASE-CTM3 Undisclosed T-cell malignancies and autoimmune disease

 

COVID-CTMs 3 targets Anti-viral

 

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryLead OptimizationPreclinicalPhase 1Phase 2Phase 3
Ligase Inhibitor Portfolio
NX-1607 CBL-B (Oral) Immuno-oncology

 

DeTIL-0255 CBL-B (ex vivo) Tumor infiltrating lymphocytes

 

LIGASE-INH2 Undisclosed Immuno-oncology

 

Drug CandidateTarget (Delivery)Therapeutic AreaDiscoveryLead OptimizationPreclinicalPhase 1Phase 2Phase 3
Partners and Subsidiaries
DeCART CBL-B and others (ex vivo) Chimeric antigen receptor T‑cells (CAR-T)

 

Gilead Sciences 5 targets Undisclosed

Undisclosed Progress

 

Sanofi 5 targets Undisclosed

Undisclosed Progress

 

Candidate / TargetPhase
Protein Degradation Chimeric Targeting Molecule (CTM) Portfolio
NX-2127
BTK + IMiD Activity (Oral)
Phase 1
NX-5948
BTK (Oral)
Preclinical
KINASE-CTM3
Undisclosed
Lead Optimization
COVID-CTMs
3 targets
Discovery
Ligase Inhibitor Portfolio
NX-1607
CBL-B (Oral)
Preclinical
DeTIL-0255
CBL-B (ex vivo)
Preclinical
LIGASE-INH2
Undisclosed
Lead Optimization
Partners and Subsidiaries
DeCART
CBL-B and others (ex vivo)
Lead Optimization
Gilead Sciences
5 targets
Undisclosed Progress
Sanofi
5 targets
Undisclosed Progress

DeTIL-0255 (drug-enhanced tumor-infiltrating lymphocytes for solid tumors)

DeTIL-0255 is a cellular therapy that incorporates our proprietary small molecule CBL-B inhibitor NX-0255 in the cell expansion process of tumor infiltrating lymphocytes (TIL). We call this drug-enhanced TIL, or DeTIL. While DeTIL-0255 incorporates a CBL-B inhibitor, we are also exploring combining other targeted agents, such as its proprietary protein degraders, to enhance T cell expansion and phenotypes.

We are planning to first develop DeTIL-0255 in multiple solid tumors as a monotherapy and later to combine it with our proprietary oral CBL-B inhibitor, NX-1607. A Phase 1 clinical trial of DeTIL-0255 in gynecological malignancies is planned to start in the second half of 2021.

DeCART (drug-enhanced chimeric antigen receptor T cells)

Nurix has established a subsidiary, DeCART, focused on drug-enhanced CAR T therapies for hematological and solid tumors. DeCART was founded by Nurix and world-renowned physician and scientist Dr. Carl June, in collaboration with his colleagues from the University of Pennsylvania.
Visit DeCART